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Abstract: Molecular pathology is an essential part of pathology complementing conventional morphologi-
cal tools to obtain a correct integrated diagnosis with appropriate assessment of prognosis and prediction
of response to therapy, particularly in cancer. There is a concern about the situation of molecular
pathology in some areas of Europe, namely, regarding the central role of pathologists in assessing so-
matic genomic alterations in cancer. In some countries, there are attempts that other laboratory medicine
specialists perform the molecular analysis of somatic alterations in cancer, particularly now when next
generation sequencing (NGS) is incorporated into clinical practice. In this scenario, pathologists may
play just the role of ”tissue providers,” and other specialists may take the lead in molecular analysis.
Geneticists and laboratory medicine specialists have all background and skills to perform genetic analysis
of germline alterations in hereditary disorders, including familial forms of cancers. However, interpreta-
tion of somatic alterations of cancer belongs to the specific scientific domain of pathology. Pathologists
are necessary to guarantee the quality of the results, for several reasons: (1) The identified molecular
alterations should be interpreted in the appropriate morphologic context, since most of them are context-
specific; (2) pre-analytical issues must be taken into consideration; (3) it is crucial to check the proportion
of tumor cells in the sample subjected to analysis and presence of inflammatory infiltrate and necrosis
should be monitored; and 4) the role of pathologists is crucial to select the most appropriate methods
and to control the turnaround time in which the molecular results are delivered in the context of an
integrated diagnosis. Obviously, there is the possibility of having core facilities for NGS in a hospital to
perform the sequence analysis that are open to other specialties (microbiologists, geneticists), but also in
this scenario, pathologists should have the lead in assessing somatic alterations of cancer. In this article,
we emphasize the importance of interpreting somatic molecular alterations of the tumors in the context
of morphology. In this Position Paper of the European Society of Pathology, we strongly support a
central role of pathology departments in the process of analysis and interpretation of somatic molecular
alterations in cancer.
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Abstract
Molecular pathology is an essential part of pathology complementing conventional morphological tools to obtain a correct
integrated diagnosis with appropriate assessment of prognosis and prediction of response to therapy, particularly in cancer.
There is a concern about the situation of molecular pathology in some areas of Europe, namely, regarding the central role of
pathologists in assessing somatic genomic alterations in cancer. In some countries, there are attempts that other laboratory
medicine specialists perform the molecular analysis of somatic alterations in cancer, particularly now when next generation
sequencing (NGS) is incorporated into clinical practice. In this scenario, pathologists may play just the role of “tissue providers,”
and other specialists may take the lead in molecular analysis. Geneticists and laboratory medicine specialists have all background
and skills to perform genetic analysis of germline alterations in hereditary disorders, including familial forms of cancers.
However, interpretation of somatic alterations of cancer belongs to the specific scientific domain of pathology. Pathologists
are necessary to guarantee the quality of the results, for several reasons: (1) The identified molecular alterations should be
interpreted in the appropriate morphologic context, since most of them are context-specific; (2) pre-analytical issues must be
taken into consideration; (3) it is crucial to check the proportion of tumor cells in the sample subjected to analysis and presence of
inflammatory infiltrate and necrosis should be monitored; and 4) the role of pathologists is crucial to select the most appropriate
methods and to control the turnaround time in which the molecular results are delivered in the context of an integrated diagnosis.
Obviously, there is the possibility of having core facilities for NGS in a hospital to perform the sequence analysis that are open to
other specialties (microbiologists, geneticists), but also in this scenario, pathologists should have the lead in assessing somatic
alterations of cancer. In this article, we emphasize the importance of interpreting somatic molecular alterations of the tumors in
the context of morphology. In this Position Paper of the European Society of Pathology, we strongly support a central role of
pathology departments in the process of analysis and interpretation of somatic molecular alterations in cancer.
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Cancer as a complex genetic and epigenetic
disease
Cancer is a complex disease. Hereditary and environmental
factors are important in its development. Cancer results from
accumulation of genetic and epigenetic alterations in cells [1],
under the influence of the immune system and the non-
neoplastic microenvironment, which is usually tumor-type
specific. Cancer cells have important interactions with non-
cancer host cell populations, such as fibroblasts, vessels, or
inflammatory cells [2].
Every type of cancer has its own molecular profile. Even
more, each individual cancer in a particular patient has its
unique repertoire of molecular abnormalities [3]. With the
exception of some types of tumors, it is virtually impossible
to find two tumors from two different patients, even from the
same organ, having the same genetic and epigenetic back-
ground. Thus, from the biological viewpoint, each tumor rep-
resents a unique scenario resulting from a sequence of indi-
vidual molecular changes. We know today that the morpho-
logic appearance of the tumors reflects the genetic and epige-
netic changes present in tumor cells. Microscopy has been
crucial in recognizing biologically distinct entities with spe-
cific molecular features, and, on the other hand, molecular
profiling has allowed identifying new tumor types that turned
out to have specific microscopic features.
Role of pathology in the diagnosis of cancer
For many years, cancer has been diagnosed on the basis of its
microscopic appearance. Several decades ago, identification
of proteins by immunohistochemistry became an important
tool in cancer diagnosis [4]. Later on, identification of single
gene alterations (mutations, gene fusions, amplifications, by
PCR-based mutation analysis, or FISH) was incorporated into
pathological report and is used today as a tool to help in diag-
nosis, prognosis, and prediction in response to treatment. Over
the years, WHO classifications of tumors have transformed
from exclusive morphologic criteria into integrated
morphologic-molecular schemes. Novel technologies like
NGS are providing more information to understand the mo-
lecular profile of each particular tumor. Bioinformatic support
is an essential tool for the analysis of large-scale molecular
datasets. Microscopic appearance, nevertheless, provides the
framework in which molecular analysis should be interpreted.
Pathology is the medical discipline responsible for the di-
agnosis of diseases based on the morphological appearance
under the microscope of tissue or cytological samples.
Cancer is one of the areas where the progress in pathology is
most dynamic and significant. The role of pathologists in di-
agnosis of cancer, as well as assessment of prognostic and
predictive factors, is crucial. The task for pathologists is not
only the evaluation of the gross appearance of the lesion to-
gether with microscopic assessment of neoplastic tissue. To
guarantee high reliability of pathological diagnosis, the so
called pre-analytical conditions (handling of the material be-
fore the testing itself) must be controlled. Another crucial
issue is the appropriate sampling of most relevant diagnostic
areas, as well as selection of the most informative tumor areas
for additional ancillary techniques [5, 6].
Generally speaking, a patient does not have a proven can-
cer diagnosis, until a pathologist establishes such diagnosis in
a histologic or cytologic specimen. Obviously, there are few
exceptions to this statement, for some malignancies and dis-
seminated tumors, in which obtaining a tissue sample may be
too risky for the patient.
Pathologists are not laboratory specialists who identify,
quantify, and report molecules from blood or other biological
samples. We are medical specialists interpreting the micro-
scopic appearance of the tumor in the setting of the molecular,
clinical, and imaging features. Occasionally, similar micro-
scopic pictures can lead to different diagnoses, depending on
age, tumor site, or clinical scenario.
Interpretation by pathologists is also essential for correct
interpretation of molecular research data resulting from the
analysis of tissues and cells [7, 8]. The anomaly of interpreting
and reporting research pathologic features in human and ani-
mal models without the appropriate expertise in pathology has
led to inadequate interpretation and occasional retraction of
erroneous results, even in highly prestigious peer-review
journals [9]. The term “pathology by yourself” or “do it your-
self” has been used to designate this incorrect way of
interpretingmolecular data, in which researchers perform their
own pathologic analysis, lacking appropriate training in pa-
thology [10]. It would be inadmissible to accept similar prac-
tice when providing pathologic diagnosis in patients’ tissue
samples (biopsies and/or surgical specimens), potentially
resulting in inappropriate or even entirely wrong decisions in
patients’ care.
Germline molecular alterations in cancer
The genetic alterations that are detected in cancer tissues can
be germline or somatic. Cancer-related germline genetic ab-
normalities occur in the setting of clinical situations with an
increased risk for the development of cancer. Familial cancer
syndromes are the paradigmatic examples. Germline alter-
ations are important for tumor development, and their identi-
fication may be important for prognosis or even for prediction
of response to certain types of systemic anticancer treatment.
Germline alterations are detected in tumor tissue but also in
normal non-neoplastic tissues from cancer patients. Peripheral
blood is the most frequently used biological material for iden-
tification of germline changes. Management of DNA and
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RNA from peripheral blood is less challenging than that ob-
tained from tumor tissue, as the nucleic acids in the blood are
less negatively influenced by pre-analytical conditions.
Identification and interpretation of germline alterations in
cancer do not usually require integration of the results in the
context of morphological features of the tumors. It may be
perfectly performed by geneticists, who have the appropriate
expertise, including skills to classify the identified variations
regarding their impact and distinguish between pathogenic
changes from those that are not. Bioinformatic support is es-
sential. Since the tumors occurring in the setting of familial
cancer syndromes may sometimes have specific morphologic
features, it is desirable to have pathologists as part of the
multidisciplinary teams interpreting results of germline mo-
lecular testing and establishing screening or surveillance strat-
egies. However, it does not seem necessary that pathologists
have the lead in these clinical strategies.
Occasionally, analysis of somatic mutations may lead to
identification of a genetic change that may be suspicious to
be in fact a germline alteration. Additional conventional
germline mutation analysis (from peripheral blood) in close
collaboration with clinical geneticist may be mandatory to
confirm the germline nature of these genetic variants.
Evidence of BRCA1/2 mutations or microsatellite instabil-
ity (Lynch syndrome) should be noted in the pathology report
with a recommendation that clinical geneticists have to be
involved to perform genetic counseling of the patient with this
family.
Importance of interpreting somatic
alterations in cancer in the appropriate
morphological context
The scenario of somatic genomic alterations of cancer is dif-
ferent from that of the germline ones. The clinical and patho-
logic contexts are important. Integration of molecular results
with microscopic features is necessary. There are tissue-
specific differences in tumorigenesis and the organization of
individual oncogenic signaling pathways. There are many ex-
amples of somatic alterations (BRAF, KIT) that have different
significance depending on tumor type [11]. There are many
evidences showing that the genomic landscape and the rele-
vance of activated signaling pathways differ with respect to
tumor type and organ location [12]. Different cells and tissues
have important differences in their response to oncogenic
driver mutations [13, 14], and cancer drivers may have differ-
ent roles in different cell types or stages of differentiation.
Recent basket trials provide evidence that the response to a
molecular alteration-specific anticancer drug often depends on
the pathologic cancer type as well as on the tissue of origin
[11]. The context-specific preservation of feedback explains
why and how oncogene addiction maintains a certain level of
signaling output and counteracting intrinsic feedback inhibi-
tion [15], depending on cell type.
Interpretation of somatic alterations of cancer should be
therefore performed in the setting of pathology departments.
In this regard, it is necessary that pathology departments in-
corporate specialists with strong molecular expertise (bio-
chemists, molecular biologists) as well as bioinformaticians,
who should be integrated as full-fledged staff members. This
is currently the situation in a significant proportion of tertiary
hospitals across Europe; however, in some areas, there are
administrative difficulties for an efficient incorporation.
Incorporation of NGS into clinical practice is having a tre-
mendous impact in management of cancer patients [16]. In
some scenarios, single-gene approaches seem to be still cost-
effective, but in steadily growing proportion of clinical situa-
tions, there is a need for multigene approach, i.e., analyzing
sets of multiple clinically relevant genes at the same time. This
strategy is saving the tissue, which is often limited, increasing
cost-efficacy, and reducing turnaround time of response. It is
the responsibility of pathologist to select, on the basis of mor-
phologic findings, the markers which should be tested and to
guarantee the choice of appropriate methods as well as opti-
mal use of the limited tissue sample. While NGS is frequently
used for identification of germline alterations in cancer, be-
cause a high number of simultaneously analyzed genes are
usually necessary, its use to identify somatic abnormalities is
also becoming more accessible.
In some centers, NGS equipment is based in pathology
departments. In other centers, NGS facility is shared in central
core facilities, available to several different specialties. In
some of these centers, pathologists have access to NGS equip-
ment and perform somatic molecular interpretation followed
by delivery of an integrated pathologic report. In other centers,
NGS is performed by other specialists, and pathologists are
only requested to simply provide tissue samples, without too
much interaction, and insufficient involvement in reporting
the results. We are strongly convinced that this role of just
“tissue providers” would be totally inappropriate, carrying
important risks of incorrect interpretation of molecular find-
ings outside of the tissue context, and might be thus potential-
ly detrimental to patient safety.
Sometimes, hospital administrators do not consider the
abovementioned conditions and take unfortunate decisions
allowing molecular testing and interpretation of cancer somat-
ic alterations in facilities, outside pathology departments,
without guaranteeing integration into the appropriate patho-
logic context. These wrong decisions are usually based on
economical or organizational parameters, not supported by
scientific evidence.
Another important fact which must be taken into consider-
ation is the issue of tumor heterogeneity. There is increasing
evidence that tumors are composed of subpopulations of cells
with distinct genetic alterations [17, 18]. Tumor heterogeneity
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has its consequences often also at the microscopic level. With
the advent of NGS techniques, the occurrence and extent of
intra-tumor heterogeneity is becoming acknowledged and cor-
relates many times with different microscopic features. Spatial
and temporal heterogeneity may permit the tumor to adapt to
variations in tumor microenvironment. Comparison of the so-
matic mutations of primary tumors and metastasis or in tumor
areas with different histological patterns indicates that somatic
gene alterations may vary substantially. It has been shown that
tumor heterogeneity can be a challenge for evaluating the
suitability of individual targeted therapies, since abnormalities
in target genes can be heterogeneously distributed in different
subpopulations of an individual tumor. Evaluation of tumor
heterogeneity at the microscopic level in conjunction with its
tumor-associated microenvironment is necessary for the opti-
mal selection of a tissue block for molecular analysis; this
step, seemingly simple, may have a crucial impact on
assessing correctly prognosis or prediction of response to
treatment.
As mentioned before, the clinical and microscopic context
is essential to interpret appropriately the results. This is rele-
vant not only for tumor morphology but also to interpret the
role of non-cancer microenvironment in conjunction with mo-
lecular data. However, it is important to emphasize that any
molecular test is just one small part of the entire complex
pathologic diagnosis. Traditional pathological features, such
as gross findings, tumor stage, histological type, and grade
based on microscopic evaluation and molecular findings,
should be therefore integrated in a combined pathologic re-
port. Moreover, digital pathology, which is recently being im-
plemented in many pathology departments, may become an
additional useful tool to integrate molecular results in the ap-
propriate pathological context [19]. Advances in digital pa-
thology will help in implementing algorithms of artificial in-
telligence, as an additional tool for integrating all information
retrieved from a cancer tissue specimen [20].
Indications for molecular analysis in pathology have
changed over the last decade. Molecular pathology was ini-
tially performed virtually exclusively for diagnostic purposes
in hematologic disorders and solid tumors, and pathologists
were the solely responsible for deciding when and which spe-
cific test should be performed in a particular case. Nowadays,
however, a significant proportion of the molecular tests are
performed for predictive purposes, to identify subsets of can-
cer patients who will have higher probability to respond to
certain anticancer treatment. This has led to a change of roles,
and the tests are now frequently requested by clinician. Under
such circumstances, a close interaction between oncologists
and pathologists is necessary, with efficient workflow and
decision-making strategies, in which Molecular Tumor
Boards are excellent scenarios. Nowadays, many pathology
departments organize Molecular Tumor Boards, involving
molecular biologists, bioinformaticians, and oncologists, to
discuss the relevance of NGS findings for targeted therapies
in different organ tumors (lung, breast, urological cancers)
together. These Molecular Tumor Boards represent ideal plat-
forms for a comprehensive discussion of all aspects of molec-
ular diagnostics and the consequences for targeted therapies. It
should be emphasized, however, that pathologist should play a
role in the decision about the most appropriate molecular as-
say that must be performed, particularly for cancer diagnosis
(Fig. 1).
The number of molecular tests that are incorporated to reg-
ular testing of tissues is constantly growing, in concordance
with development of novel targeted therapies requiring new
predictive biomarkers [21]. In this scenario, pharmaceutical
companies involved in the development of innovative treat-
ment are becoming new actors, and their important role has to
be taken into account. However, this is a two-side process.
Recent experience from development of new checkpoint in-
hibitors clearly demonstrates that pathologists should be in-
volved also in the planning of new clinical trials, regarding
eligibility, stratification, quality control, and particularly pa-
rameters for evaluation of response to therapy, and establish-
ment of criteria for scoring predictive biomarkers. Only so we
can eliminate (or at least minimize) later complications and
issues during the implementation of testing after the drug
approval.
Currently, a new paradigm for cancer care is emerging,
where treatments are identified based on the specific genetic
profile of an individual’s tumor, regardless of where it first
originated. Pathologists diagnose tumors based on a specific
histological type and the organ of origin. However, organiza-
tions such as the American Food and Drug Administration
(FDA) have recently shown a willingness to accept novel trial
designs—such as basket studies, which enroll patients for
treatments based on the biology of their tumor, not their tumor
type. These “tumor-agnostic” agents target gene alterations
thought to drive tumor growth regardless of cancer histology.
“Tumor-agnostic” therapies are based on identification of mi-
crosatellite instability or high tumor mutational burden for
immuno-oncological therapies [22]. Other examples include
TRK inhibitors, showing clinically meaningful responses in
patients with NTRK fusions. NTRK gene fusions are present
in a broad range of more than 20 different tumor types, in-
cluding those of the head and neck, salivary gland, bladder,
and lung [23, 24]. It is the task of pathologists to proof this
controversial concept and to evaluate such tumor-agnostic
treatments. It is currently not clear to what extent tumor-
agnostic therapies will be implemented at the long term and,
also, whether theywill be limited to a few drugs or extended to
a high number of agents. Part of the pathology community is
skeptical, based on the specificities of signaling pathway ac-
tivation regarding histological type and organ of origin. It is
evident, however, that pathologists should be ready to incor-
porate biomarker identification of these agnostic therapy-
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related markers that will probably coexist in the future with
tumor-specific predictive biomarkers. Even in this scenario,
interpretation of molecular findings should be done in the
setting of microscopical appearance and control of pre-
analytical conditions.
Moreover, incorporation of somatic molecular testing inte-
grated in pathology has a profound positive impact on attrac-
tiveness of pathology as a medical discipline in medical stu-
dents who may decide to become pathologists. Furthermore, it
has also important positive consequences in training and post-
graduate education. The responsibility of incorporating mo-
lecular assays into routine pathology also requires deep under-
standing of the field by pathologists, not only for those direct-
ly involved in the workflow of the molecular tests.
An international strategy should be considered to give sup-
port to countries where molecular pathology is performed so
far only in minimal extent, in order to face the scenario of
increasing technological complexity and hardware require-
ments [25].
The issue of liquid biopsy (testing of circulating cell-free
DNA released by the tumor—ctDNA) was not within the
scope of this paper, which was exclusively focused on somatic
molecular testing in tumor tissue. However, it is a very prom-
ising technique, regularly performed in many pathology de-
partments across Europe. Although, at present, it is limited to
a selected group of neoplasms such as lung cancer, its use will
be probably extended also to other types of cancer in the near
future.
Technical issues
Technical issues are important to obtain correct results
[26–30]. Pathology departments are responsible for providing
the appropriate pre-analytical conditions which are crucial to
get correct results. The control of pre-analytical factors is
included also in the ISO15189 standard, which is to be follow-
ed to fulfill all conditions important for quality control of
pathology departments and molecular laboratories. In
Europe, the technical specifications for pre-analytics, issued
by CEN (European Committee for Standardization) (https://
www.cen.eu), should be applied. These are then translated
into ISO international standards after 1 or 2 years.
Involvement of pathologists in the entire process of
molecular analysis ensures optimization of pre-analytical var-
iables, such as cold ischemia time and optimal fixation.
Quality control is a very important issue. Pathology depart-
ments should demonstrate to be capable to perform somatic
molecular testing in optimal conditions, at all steps of the
technical process at the pre-analytical, analytical, and post-
analytical levels. External quality control by accredited agen-
cies is required.
Cold ischemia time is the period between tissue surgical
removal and fixation. It is an important factor, since DNA,
RNA, and proteins are altered during such period, with a clear
impact on the results of testing using molecular techniques
[30]. Tissue samples submitted to inappropriate fixation (too
short, too long, inadequate concentration of fixative, etc.) may
also yield incorrect results. Moreover, there are different pro-
tocols for paraffin-embedding as well as variations in this
process that can affect the quality of the nucleic acids within
the tissues.
As mentioned before, selection of the appropriate tissue
block for molecular analysis is crucial in the light of tumor
heterogeneity [31]. It is important to guarantee the optimal
absolute number of neoplastic cells, as well as to quantify
percentage of neoplastic cells in relation to non-neoplastic
elements, such as inflammatory infiltrate, fibroblasts, and oth-
er cells of the tumor stroma. Presence of necrosis may con-
tribute to difficulties to get correct results. Necrotic areas
should be excluded from testing. If this is not possible, the
amount of necrosis has to be quantified. Macro- or micro-
Fig. 1 Workflow diagram of
somatic molecular testing
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dissection is frequently necessary to ensure the best quality of
the tumor fragment for molecular analysis, and this can only
be done by individuals with expertise in pathology.
Occasionally, the initially selected tumor tissue fragment does
not fulfill criteria for quality control, which leads to repetition
of the procedure and selection of another tissue sample.
Sometimes, the tissue does not fulfill quality requirements
for NGS, and material may be submitted to analysis by an
alternative single-gene approach. This workflow should fol-
low standardized protocols to ensure appropriate turnaround
times. Taking all these factors into account, a close integration
of molecular testing into routine workflow of pathology de-
partments is very important to guarantee the shortest turn-
around time for interpretation of the results. This may have
an important impact on initiation of appropriate treatment,
namely, in patients with advanced disease.
Conclusions
In this article, the importance of interpreting somatic molecu-
lar alterations of tumors in the light of morphology has been
emphasized. A central role of pathology departments is nec-
essary in the process of analysis and interpretation of somatic
genomic alterations in cancer, not just as tissue providers for
their interpretation outside this context. There are many rea-
sons from the scientific, technical, and logistics points of view.
The issue is important in terms of patient safety, since patients
deserve clinically relevant interpretation of somatic alterations
in cancer, being performed and interpreted under optimal con-
ditions, quality control of the whole procedure, and optimal
turnaround time.
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